/
Respiratory
Chronic Obstructive Pulmonary Disease
74
Pipeline Programs↗
108
Active Trials↗
80
Companies Involved↗
Chronic Obstructive Pulmonary Disease is a moderately active landscape with 74 programs across 80 companies. The most active players are CSPC ZhongQi Pharmaceutical Technology Co., Ltd., GSK, Nanjing Chia-tai Tianqing Pharmaceutical. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical51
Phase 14
Phase 211
Phase 38
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
66 of 71 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 71 classified programs, each share of the total. Modality classified for 99% of 74 pipeline programs.
Analysis
Trial Status
844
clinical trials
Completed604 · 72%
Terminated63 · 7%
Recruiting54 · 6%
Unknown status48 · 6%
Not yet recruiting40 · 5%
Withdrawn19 · 2%
Other16 · 2%
Clinical Trials
Trial Activity
844 trials
Page 1 of 57
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)